BC Innovations | Sep 17, 2009
Cover Story

Rational attack on HIV

An industry-academic partnership has reported the first fruit of an effort to identify new targets for HIV vaccines. 1 The project, spearheaded by the International AIDS Vaccine Initiative , identified a potential weak spot on the...
BioCentury | Nov 17, 2008
Finance

Ebb & Flow

Two of the many micro-cap companies with a year or less of cash secured some breathing room last week. Cardiovascular and gastrointestinal company ARYx (NASDAQ:ARYX) raised $21.6 million in a private placement, while stem cell...
BC Innovations | Oct 9, 2008
Tools & Techniques

mAbs from mammalian cells

Cytos Biotechnology AG has developed an antibody platform that employs mammalian cell display to isolate high-affinity human antibodies faster-and possibly with greater diversity-than phage display. 1 The company already has identified a possible development candidate...
BioCentury | Dec 3, 2007
Finance

Ebb & Flow

It took less than a month for Frazier Healthcare Ventures to close its sixth fund at $600 million, bringing its funds under management to over $1.8 billion. "We sent out the PPM (private placement memorandum)...
BioCentury | Oct 29, 2007
Finance

Ebb & Flow

Biogen Idec (BIIB) was off last week on slowing sales of Avonex interferon beta-1a, eroding $3.50 to $76.72 for the week. On the company's conference call, President and CEO James Mullen said 3Q07 sales of...
BioCentury | Aug 6, 2007
Finance

Ebb & Flow

With all the big names accounted for in the 2Q07 earnings season, the Street has rendered its verdict on the prospects going forward, punishing big pharma while giving big biotech at least the benefit of...
BC Week In Review | May 28, 2007
Company News

Spaltudaq management update

Spaltudaq Corp. , Seattle, Wash.   Business: Cancer, Infectious   Hired: Matthew Moyle as SVP and chief development officer, formerly an industry consultant; and Russ Hawkinson as VP of finance and administration, formerly VP of finance...
BioCentury | Apr 16, 2007
Emerging Company Profile

Corporate Profile

Spaltudaq Corp. Seattle, Wash. Technology: Human B cell-based monoclonal antibody discovery platform Disease focus: Cancer, infectious Clinical status: Late research/early preclinical Founded: 2004 by Johnny Stine University collaborators: ND Corporate partners: None Number of employees:...
BioCentury | Apr 16, 2007
Emerging Company Profile

Spaltudaq: B-ing better

Spaltudaq Corp. thinks it has found a way to generate disease-specific human monoclonal antibodies in a fraction of the time required by human transgenic mouse methods. Moreover, the company expects its technique to generate a...
BC Week In Review | Mar 26, 2007
Company News

Spaltudaq board of directors update

Spaltudaq Corp. , Seattle, Wash.   Business: Cancer   Appointed: Wende Hutton, a venture partner at Canaan Partners; and Christopher Mirabelli, a managing director at HealthCare Ventures LLC  ...
Items per page:
1 - 10 of 11
BC Innovations | Sep 17, 2009
Cover Story

Rational attack on HIV

An industry-academic partnership has reported the first fruit of an effort to identify new targets for HIV vaccines. 1 The project, spearheaded by the International AIDS Vaccine Initiative , identified a potential weak spot on the...
BioCentury | Nov 17, 2008
Finance

Ebb & Flow

Two of the many micro-cap companies with a year or less of cash secured some breathing room last week. Cardiovascular and gastrointestinal company ARYx (NASDAQ:ARYX) raised $21.6 million in a private placement, while stem cell...
BC Innovations | Oct 9, 2008
Tools & Techniques

mAbs from mammalian cells

Cytos Biotechnology AG has developed an antibody platform that employs mammalian cell display to isolate high-affinity human antibodies faster-and possibly with greater diversity-than phage display. 1 The company already has identified a possible development candidate...
BioCentury | Dec 3, 2007
Finance

Ebb & Flow

It took less than a month for Frazier Healthcare Ventures to close its sixth fund at $600 million, bringing its funds under management to over $1.8 billion. "We sent out the PPM (private placement memorandum)...
BioCentury | Oct 29, 2007
Finance

Ebb & Flow

Biogen Idec (BIIB) was off last week on slowing sales of Avonex interferon beta-1a, eroding $3.50 to $76.72 for the week. On the company's conference call, President and CEO James Mullen said 3Q07 sales of...
BioCentury | Aug 6, 2007
Finance

Ebb & Flow

With all the big names accounted for in the 2Q07 earnings season, the Street has rendered its verdict on the prospects going forward, punishing big pharma while giving big biotech at least the benefit of...
BC Week In Review | May 28, 2007
Company News

Spaltudaq management update

Spaltudaq Corp. , Seattle, Wash.   Business: Cancer, Infectious   Hired: Matthew Moyle as SVP and chief development officer, formerly an industry consultant; and Russ Hawkinson as VP of finance and administration, formerly VP of finance...
BioCentury | Apr 16, 2007
Emerging Company Profile

Corporate Profile

Spaltudaq Corp. Seattle, Wash. Technology: Human B cell-based monoclonal antibody discovery platform Disease focus: Cancer, infectious Clinical status: Late research/early preclinical Founded: 2004 by Johnny Stine University collaborators: ND Corporate partners: None Number of employees:...
BioCentury | Apr 16, 2007
Emerging Company Profile

Spaltudaq: B-ing better

Spaltudaq Corp. thinks it has found a way to generate disease-specific human monoclonal antibodies in a fraction of the time required by human transgenic mouse methods. Moreover, the company expects its technique to generate a...
BC Week In Review | Mar 26, 2007
Company News

Spaltudaq board of directors update

Spaltudaq Corp. , Seattle, Wash.   Business: Cancer   Appointed: Wende Hutton, a venture partner at Canaan Partners; and Christopher Mirabelli, a managing director at HealthCare Ventures LLC  ...
Items per page:
1 - 10 of 11